Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12

Benzinga Newsdesk www.benzinga.com Neutral 53.4%

Neg 0% Neu 53.4% Pos 0%

Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announces Price Target of $12.